Article
Refine
Year of publication
- 2019 (500) (remove)
Document Type
- Article (500) (remove)
Has Fulltext
- yes (500)
Is part of the Bibliography
- no (500)
Keywords
- inflammation (10)
- glioblastoma (8)
- cancer (7)
- Breast cancer (6)
- biomarker (6)
- Inflammation (5)
- breast cancer (5)
- immunotherapy (5)
- mTOR (5)
- Biomarkers (4)
- Chemotherapy (4)
- Gene expression (4)
- Human behaviour (4)
- Oncology (4)
- autophagy (4)
- cirrhosis (4)
- fMRI (4)
- glioma (4)
- hypoxia (4)
- infection (4)
- invasion (4)
- macrophage (4)
- microRNA (4)
- mitochondria (4)
- Aortic valve (3)
- Cancer treatment (3)
- Children (3)
- Cirrhosis (3)
- Death rates (3)
- Depression (3)
- Drug therapy (3)
- Germany (3)
- HDAC (3)
- Hemorrhage (3)
- Immunotherapy (3)
- Mental health and psychiatry (3)
- Molecular neuroscience (3)
- Multivariate analysis (3)
- Neutropenia (3)
- Outcome (3)
- Predictive markers (3)
- Prognosis (3)
- Prävention (3)
- Quality of life (3)
- Research article (3)
- T cells (3)
- acute coronary syndrome (3)
- angiogenesis (3)
- complications (3)
- cytokines (3)
- differentiation (3)
- efficacy (3)
- epilepsy (3)
- integrin (3)
- leukemia (3)
- macrophage polarization (3)
- macrophages (3)
- monocytes (3)
- mycophenolic acid (3)
- neoadjuvant therapy (3)
- p21 (3)
- peripheral artery disease (3)
- prevention (3)
- reactive oxygen species (3)
- risk factors (3)
- sepsis (3)
- surgery (3)
- tumor microenvironment (3)
- vitamin D (3)
- Acute inflammation (2)
- Acute myeloid leukemia (2)
- Adverse events (2)
- Age groups (2)
- Alpelisib (2)
- Apoptosis (2)
- Aspergillus fumigatus (2)
- Atezolizumab (2)
- B cells (2)
- Biomarker (2)
- Body mass index (2)
- CAD/CAM (2)
- CC16 (2)
- CDKN1A (2)
- CIK cells (2)
- Cancer (2)
- Cancer chemotherapy (2)
- Cancer genomics (2)
- Cardiac hypertrophy (2)
- Cell differentiation (2)
- Cell proliferation (2)
- Clinical presentation (2)
- Cognition (2)
- Crohn’s disease (2)
- Cytokines (2)
- DMEK (2)
- DNA methylation (2)
- Developmental biology (2)
- Diagnostic medicine (2)
- Digestive system procedures (2)
- EGFR (2)
- Ears (2)
- Ejection fraction (2)
- Endothelial cells (2)
- Epidemiology (2)
- Fatty liver (2)
- HBV (2)
- HSV (2)
- Heart (2)
- Heart failure (2)
- Hepatitis C virus (2)
- Hospitals (2)
- Hypertension (2)
- IBD (2)
- Incidence (2)
- Infectious diseases (2)
- Inflammatory diseases (2)
- Ischemia (2)
- Katherine (2)
- Knowledge (2)
- Liver diseases (2)
- MYC (2)
- Machine learning (2)
- Macrophages (2)
- Magnetic resonance imaging (2)
- Mammakarzinom (2)
- Mesenchymal stem cells (2)
- Messenger RNA (2)
- Metastasen (2)
- Molecular medicine (2)
- Mouse (2)
- NADPH oxidase (2)
- Obesity (2)
- Ophthalmology (2)
- Outcomes (2)
- PARP (2)
- PD-L1 (2)
- PD‑L1 (2)
- PI3K (2)
- Patients (2)
- Pediatric infections (2)
- Personalized medicine (2)
- Pregnancy (2)
- Psychiatric disorders (2)
- RITA (2)
- Radiomics (2)
- Sepsis (2)
- Sleep (2)
- Stroke (2)
- Suicide (2)
- Supportivtherapie (2)
- Surgery (2)
- Surgical and invasive medical procedures (2)
- Surgical oncology (2)
- Transcription factors (2)
- Treatment (2)
- T‑DM1 (2)
- additives (2)
- adjuvant therapy (2)
- adjuvante Therapie (2)
- advanced (2)
- aged (2)
- alirocumab (2)
- alpelisib (2)
- antiviral therapy (2)
- apoptosis (2)
- arteriogenesis (2)
- astrocytes (2)
- atezolizumab (2)
- attention (2)
- bone metabolism (2)
- brain metastases (2)
- caspase-2 (2)
- cholesterol (2)
- chronic kidney disease (2)
- classical Hodgkin lymphoma (2)
- cognition (2)
- colorectal cancer (2)
- complement (2)
- corneal edema (2)
- corneal transplantation (2)
- curcumin (2)
- cyclosporin A (2)
- cytomegalovirus (2)
- data science (2)
- dementia (2)
- dental implant (2)
- early breast cancer (2)
- echocardiography (2)
- eicosanoids (2)
- electrolytic cleaning (2)
- environmental tobacco smoke (2)
- extracellular matrix (2)
- fortgeschritten (2)
- frühes Mammakarzinom (2)
- graph theory (2)
- heart failure (2)
- hematopoietic stem cell transplantation (2)
- hepatitis C virus (2)
- human (2)
- immune evasion (2)
- innate immunity (2)
- integrins (2)
- liver disease (2)
- lncRNA (2)
- magnetic resonance imaging (2)
- metabolic syndrome (2)
- metastatic (2)
- methylprednisolone (2)
- migration (2)
- modularity (2)
- mortality (2)
- multiple sclerosis (2)
- music (2)
- neoadjuvante Therapie (2)
- obesity (2)
- osteoporosis (2)
- particulate matter (2)
- periimplantitis (2)
- pharmacovigilance (2)
- phosphorylation (2)
- portal hypertension (2)
- primary care (2)
- primary health care (2)
- proliferation (2)
- prostaglandins (2)
- prostate cancer (2)
- proteome (2)
- proteomics (2)
- psoriasis (2)
- quantitative MRI (2)
- radical prostatectomy (2)
- radiotherapy (2)
- registry (2)
- renal function (2)
- secretome (2)
- signal transduction (2)
- sphingosine-1-phosphate (2)
- supportive therapy (2)
- targeted therapy (2)
- transplantation (2)
- trauma (2)
- tumor-associated macrophages (2)
- uteroglobin (2)
- (novel) brominated flame retardants ((N)BFR) (1)
- (surface) partial differential equations (1)
- 15-PGDH (1)
- 3Cs technology (1)
- 3D spatiotemporal resolved mathematical models (1)
- 3D tissue models (1)
- 3years (1)
- 5' UTR (1)
- 6-Schritt-Methode (1)
- A375 human melanoma cell line (1)
- AB-serum (1)
- ACL (1)
- ACLF (1)
- AICAR (1)
- AIS (1)
- ALF (1)
- AMD3100 (1)
- AML (1)
- AMPK (1)
- APRI (1)
- ASCT (1)
- AT-101 (1)
- ATG4 (1)
- ATG8 (1)
- ATM (1)
- ATO (1)
- AVM hemorrhage (1)
- Abdominal surgery (1)
- Abdominal trauma (1)
- Abiraterone acetate (1)
- Actinomycin D (1)
- Action potential (1)
- Addison’s disease (1)
- Adenocarcinoma (1)
- Adhesins (1)
- Adhesion (1)
- Adipose-derived mesenchymal stem cells (1)
- Adjustment of dosage at steady state (1)
- Adolescents (1)
- Agoraphobia (1)
- Akutes Koronarsyndrom (1)
- Alleles (1)
- Allergen immunotherapy (1)
- Allergoid (1)
- Aminotransferases (1)
- Anemia (1)
- Anesthesia, Intravenous (1)
- Aneurysmal subarachnoid hemorrhage (1)
- Aneurysms (1)
- Angiogenesis (1)
- Angiography (1)
- Anosmia (1)
- Antibody isotypes (1)
- Anticoagulants [MeSH] (1)
- Anticoagulation (1)
- Antigen-presenting cells (1)
- Antigens (1)
- Antiplatelet therapy (1)
- Antireflux surgery (1)
- Antiviral therapy (1)
- Anura (1)
- Aortic aneurysm (1)
- Aortic arch replacement (1)
- Aortic dissection (1)
- Aortic stenosis (1)
- Aortic stiffness (1)
- Aortic valve replacement (1)
- Aortic valve sparing (1)
- Apes (1)
- Arabin pessary (1)
- Arabin-Pessar (1)
- ArchT (1)
- Aromatase Inhibitors (1)
- Arrhythmia (1)
- Artificial intelligence (1)
- Aspergillus species (1)
- Asphyxia (1)
- Ataxia telangiectasia (1)
- Atelopus carbonerensis (1)
- Atelopus mucubajiensis (1)
- Atelopus tamaense (1)
- Atrial fibrillation (1)
- Attention (1)
- Attitude (1)
- Audio equipment (1)
- Audio signal processing (1)
- Audiology (1)
- Aurora A (1)
- Aurora Ax (1)
- Australia (1)
- Austria (1)
- Automated sRNA analysis (1)
- Autophagy (1)
- Awareness (1)
- Axon (1)
- B cell malignancies (1)
- B cell precursor acute lymphoblastic leukemia (1)
- B-cell antigen receptor (1)
- BBB (1)
- BCL2 (1)
- BI1361849 (1)
- BIAM switch assay (1)
- BMAC (1)
- BNC2 (1)
- BRAF mutation (1)
- Back pain (1)
- Bartonella (1)
- Biliary tree (1)
- Bilirubin (1)
- Biomarkers & Diagnostic Imaging (1)
- Biotechnology (1)
- Bipolar disorder (1)
- Blood (1)
- Blood groups (1)
- Blood plasma (1)
- Blood pressure (1)
- Blood-brain barrier (1)
- BluePrint (1)
- Body-contouring surgery (1)
- Bone marrow (1)
- Bone marrow aspirate concentrate (1)
- Bone marrow aspiration (1)
- Bone strength assessment (1)
- Borrelia (1)
- Brain metastasis (1)
- Breast neoplasms (1)
- Breast tumors (1)
- Bufonidae (1)
- Burst (1)
- C-reactive protein (1)
- C-reactive proteins (1)
- C1 esterase inhibitor (human) (1)
- C1-esterase inhibitor protein (1)
- C3M (1)
- C4M (1)
- CAM (1)
- CD271 (1)
- CD3/CD19 depletion (1)
- CD36 (1)
- CD45RA naïve lymphocytes (1)
- CD8+ T lymphocytes (1)
- CD8+ tumor infiltrating lymphocytes (1)
- CHA2DS2-VASc-score (1)
- CHIP (1)
- CLP (1)
- CREB inhibitor (1)
- CRISPR/Cas (1)
- CRM (1)
- CRT-D (1)
- CTLA-4 (1)
- CV9202 (1)
- CVD biomarker (1)
- CVID (1)
- CWS Studiengruppe (1)
- CXCL12 (1)
- Caco-2 cells (1)
- Canada (1)
- Cancer detection and diagnosis (1)
- Cancer epidemiology (1)
- Cancer genetics (1)
- Cancer risk factors (1)
- Cancer therapeutic resistance (1)
- Cannabis (1)
- Carcinoma, Ductal, Breast (1)
- Cardiac device therapy (1)
- Cardiac monitoring (1)
- Cardiac necroenzymes (1)
- Cardiac remodelling (1)
- Cardiology (1)
- Cardiovascular Magnetic Resonance (CMR) (1)
- Cardiovascular epidemiology (1)
- Case management [MeSH] (1)
- Cell binding (1)
- Cell biology (1)
- Cell motility (1)
- Cell therapy (1)
- Cellular stress responses (1)
- Center-specific time in therapeutic range (cTTR) (1)
- Central nervous system metastases (1)
- Cerebral toxoplasmosis HIV (1)
- Cerebral vasospasm (1)
- Cesarean section (1)
- Chaperone (1)
- Chemical company (1)
- Chemosensitivity (1)
- Chlorides (1)
- Cholesterin (1)
- Chromatin accessibility (1)
- Chronic disease [MeSH] (1)
- Chronic health condition (1)
- Chronic hepatitis (1)
- Chronic hepatitis C virus (1)
- Chronic kidney disease (1)
- Chronic obstructive pulmonary disease (1)
- Citation analysis (1)
- Clincial pharmacology (1)
- Clinical effectiveness (1)
- Clinical pathways (1)
- Clinical studies (1)
- Clinical trial (1)
- Clostridioides difficile (1)
- Cognitive impairment (1)
- Cognitive neuroscience (1)
- Cognitive psychology (1)
- Colchicum (1)
- Collagen (1)
- Collagens (1)
- Colloids (1)
- Colorectal cancer (1)
- Combined immune checkpoint blockade (1)
- Community based intervention (1)
- Community health services (1)
- Comparative analysis (1)
- Complement cascade (1)
- Complication management (1)
- Comprehensive cancer centers (1)
- Computational biology and bioinformatics (1)
- Computational model (1)
- Computational sRNA analysis (1)
- Conduct disorder (1)
- Congenital duodenal obstruction (1)
- Contrast-enhanced (1)
- Cornea (1)
- Coronary heart disease (1)
- Cost-effectiveness (1)
- Cost-effectiveness analysis (1)
- Costs (1)
- Crispr/Cas (1)
- Cross-frequency coupling (1)
- Cross-sectional study (1)
- Cumulative dose (1)
- Cure (1)
- Curvilinear dose response (1)
- Cytochrome P450 enzymes (1)
- Cytogenetics (1)
- Cytoplasm (1)
- Cytoplasmic staining (1)
- Cytoskeletal proteins (1)
- Cytoskeleton (1)
- C‐reactive protein (1)
- DDA (1)
- DDIT4 (1)
- DHA (1)
- DILI (1)
- DME (1)
- DNA damage (1)
- DNA damage response (1)
- DNA repair (1)
- DNA-binding proteins (1)
- DNase1-seq (1)
- DSAEK (1)
- DUBs (1)
- Data mining (1)
- Data processing (1)
- Data science (1)
- David technique (1)
- Decision (1)
- Decision impact (1)
- Decision trees (1)
- Delayed union (1)
- Deletion mutation (1)
- Dental education (1)
- Dental students (1)
- Diagnosis (1)
- Diagnostic markers (1)
- Diagnostic test (1)
- Direct Acting Antivirals (DAA) (1)
- Direct acting antiviral therapies (1)
- Disabling back pain (1)
- Disease burden (1)
- Docetaxel (1)
- Dog (1)
- Dopamine (1)
- Dorsolateral prefrontal cortex (1)
- Doxorubicin (1)
- Dual energy CT (1)
- Duodenal atresia (1)
- Duodenal stenosis (1)
- E protein structure (1)
- EEG (1)
- EGFP (1)
- EGFR inhibitor (1)
- ENCODE-DREAM in vivo Transcription Factor binding site prediction challenge (1)
- EPA (1)
- ERK3/MAPK6 (1)
- ERM (1)
- ERP (1)
- Economic analysis (1)
- Economics (1)
- Edentulous jaw (1)
- Education (1)
- Eicosanoids (1)
- Einreibetechnik (1)
- Electrical accident (1)
- Electrical stimulation (1)
- Electroencephalography – EEG (1)
- Electrolytes (1)
- Electrophysiology (1)
- Emergency (1)
- Emotion processing (1)
- Emotion regulation (1)
- Emotions (1)
- Empfehlungen (1)
- Employment (1)
- EndMT (1)
- Endoscopy (1)
- Ensemble learning (1)
- Enterobacteriaceae (1)
- Entfernung (1)
- Enzyme regulation (1)
- Enzyme-linked immunoassays (1)
- Epilepsy (1)
- Erythropoiesis (1)
- Esophageal adenocarcinoma (1)
- Esophageal adenocarcinoma (EAC) (1)
- Esophagectomy (1)
- Estrogen Receptor Modulators (1)
- Eukaryotic sRNA (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- Evaluation (1)
- Evaluationspraxis (1)
- Evidence based medicine (1)
- Exercise challenge at an ambient temperature (1)
- Exercise challenge in a cold chamber (1)
- Exercise-induced bronchoconstriction (1)
- Experimental models of disease (1)
- Extended Glasgow outcome scale (eGOS) (1)
- Extracellular matrix proteins (1)
- Extracellular signal-regulated kinase 1/2 (1)
- Eyes (1)
- FAK (1)
- FFLU (1)
- FFPE (1)
- FIB-4 (1)
- Fatty acids (1)
- FemNAT-CD (1)
- Female adolescents (1)
- Femoral neck (1)
- Fevers (1)
- Fibroblast growth factor (1)
- Fibronectin (1)
- Fibrosis (1)
- Filovirus cell entry; attachment factors redundancy; SH-SY5Y cell line; host–pathogen interactions (1)
- Finite Volumes (1)
- First site of metastatic disease (1)
- Fistula (1)
- Flaps (1)
- Fluorescence-in-situ-hybridization (FISH) (1)
- Foramen ovale (1)
- Forkhead box (1)
- Fracture risk (1)
- Francisella tularensis (1)
- Francisella tularensis subspecies holarctica (1)
- Frühgeburt (1)
- Functional electrical stimulation (1)
- Functional magnetic resonance imaging (1)
- Functional outcome (1)
- Funding (1)
- FungiScope® registry (1)
- G-protein (1)
- G/P (1)
- GRK2 (1)
- Gait analysis (1)
- Galleria mellonella (1)
- Gastric cancer (1)
- Gastroesophageal reflux disease (1)
- Gastroesophageal reflux disease symptoms (1)
- Gaucher disease type III (1)
- Gaucher’s disease (1)
- Gender reassigning surgery (1)
- Gene prediction (1)
- Gene regulation (1)
- General practice (1)
- General practitioner (1)
- General practitioners (1)
- Generation Y (1)
- Genome annotation (1)
- Genomic instability (1)
- German PID-NET registry (1)
- German people (1)
- Gleason upgrading (1)
- Glioblastoma (1)
- Global health (1)
- Glomerular Filtration Rate (1)
- Glucose Transporter Type 1 (1)
- Glycogen synthase kinase 3 beta (1)
- Goserelin (1)
- Grafts (1)
- Gram-negative bacteria (1)
- Grass pollen (1)
- Growth factors (1)
- Guided surgery (1)
- HAEGARDA (1)
- HAI‐1 (1)
- HCV (1)
- HDACi (1)
- HER2/neu (ERBB2) (1)
- HGF (1)
- HIF1α (1)
- HIV (1)
- HNSCC (1)
- HOD (1)
- HODE (1)
- HPV (1)
- HSV-1 (1)
- HSV-2 (1)
- HUVEC (1)
- Haplotypes (1)
- Head and neck Cancer (1)
- Health care (1)
- Health economics (1)
- Health services research [MeSH] (1)
- Healthcare worker (1)
- Hedgehog (1)
- Hemoglobin (1)
- Hemophilia A (1)
- Hemorrhagic shock (1)
- HepG2 (1)
- HepaRG cells (1)
- Hepatitis B (1)
- Hepatitis B infection (1)
- Hepatitis B vaccination (1)
- Hepatitis C (1)
- Hepatocytes (1)
- Hereditary angioedema (1)
- High-risk patient (1)
- Hippo signaling (1)
- Hippocampus (1)
- Histology (1)
- Hodgkin lymphoma (1)
- Holmes tremor (1)
- Homeostasis (1)
- Homicide (1)
- Hospitalizations (1)
- Host-directed therapies (1)
- Huh7 (1)
- Human (1)
- Human genetics (1)
- Human olfaction (1)
- Humeral fractures (1)
- Humerus (1)
- Hungary (1)
- Hydrocephalus (1)
- Hyperammonemic encephalopathy (1)
- Hypofractionated radiotherapy (1)
- Hypoxic responses (1)
- I-FABP (1)
- ICU (1)
- IGF (1)
- IL-15 (1)
- IL-1β (1)
- IL-21 (1)
- IL-27 cytokine (1)
- IL-33 (1)
- IL10R (1)
- ILUVIEN (1)
- IPEX (1)
- IPS e.max system (1)
- ISS (1)
- IUIS classification 2017 (1)
- IgE (1)
- IgG substitution therapy (1)
- IgGAM (1)
- Illumina (1)
- Image analysis (1)
- Imaging genetics (1)
- Immediate loading (1)
- Immediate placement (1)
- Immune Response (1)
- Immune cells (1)
- Immunoassays (1)
- Immunogenicity (1)
- Immunohistochemistry (1)
- Immunohistochemistry techniques (1)
- Immunomonitoring (1)
- Immunostaining (1)
- Immunosuppressive Agents (1)
- Implant-supported bars (1)
- In-line filtration (1)
- IncL (1)
- Incidence rate (1)
- Independent laboratories (1)
- Indirect-binding (1)
- Individual differences (1)
- Infarction (1)
- Infusion management (1)
- Insulin resistance (1)
- Integrated multimodal training (1)
- Intelligence (1)
- Intelligence tests (1)
- Intensive care (1)
- Intensive care units (1)
- Interleukin-17A (1)
- Interleukin-18 (1)
- Interleukin-18 binding protein (1)
- Interleukin-22 (1)
- Interleukin-22 binding protein (1)
- Interventional Trials (1)
- Interventional cardiology (1)
- Intracranial embolism (1)
- Intraoral scanners (1)
- Invasive fungal infection (1)
- Invasive fungal infections (1)
- Ipilimumab (1)
- Ireland (1)
- Iron deficiency (1)
- Iron deficiency anemia (1)
- JAK inhibition (1)
- Joint loading (1)
- KIF (1)
- KIF11 (1)
- Karyotypes (1)
- Ketogenic Diet (1)
- L-DOPA (1)
- LAMTOR2 (1)
- LC-NE system (1)
- LC3 I/II (1)
- LC–MS/MS (1)
- LDL (1)
- LM11A 31 (1)
- LN229 (1)
- LPP (1)
- LRBA (1)
- LSCC (1)
- LSD1 (1)
- LUT (1)
- Labor and delivery (1)
- Laboratory techniques and procedures (1)
- Lafora disease (1)
- Laminin (1)
- Laparoscopic fundoplication (1)
- Late Gadolinium Enhancement (LGE) (1)
- Late presentation (1)
- Left hemisphere (1)
- Leg alignment (1)
- Legs (1)
- Leistungsorientierte Mittelvergabe (1)
- Lesion (1)
- Lesions (1)
- Liver (1)
- Liver Transplantation (1)
- Liver cancer (1)
- Liver fibrosis (1)
- Liver-Related Complications (1)
- Lomentospora prolificans (1)
- Long noncoding RNA (1)
- Long term output (1)
- Long-term (1)
- Luciferase (1)
- Lumbar spine (1)
- Lyme disease (1)
- Lymph nodes (1)
- Lymphadenopathy (1)
- Lymphangioleiomyomatosis (1)
- Lymphocytes (1)
- Lymphoid tissues (1)
- Lymphomas (1)
- Lysosomal storage disease (1)
- MAIT cell (1)
- MALAT1 (1)
- MEG (1)
- MMP2 (1)
- MRI patterns of gliomas (1)
- MRSA (1)
- Machine-learning (1)
- Magnetic resonance imaging (MRI) (1)
- Malaria prevalence (1)
- MammaPrint (1)
- Mammaplasty (1)
- Markov model (1)
- Masquelet technique (1)
- Mass spectrometry (1)
- Mastectomy (1)
- Maxillary sinus (1)
- Mechanisms of disease (1)
- Meckel’s diverticulum (1)
- Medical education (1)
- Medical research (1)
- Medicine and health sciences (1)
- Membrane potential (1)
- Mesenchymal stem cell (1)
- Mesenchymal stromal cells (1)
- Metabolic syndrome (1)
- Metabolism (1)
- Metabolism, Inborn Errors (1)
- Metalloproteases (1)
- Metastasis (1)
- Metastatic castration-resistant prostate cancer (1)
- Metastatic tumors (1)
- Methacholine challenge test (1)
- Methicillin-resistant Staphylococcus aureus (1)
- MiSpEx Network (1)
- MicroRNAs (1)
- Microbiome (1)
- Microphones (1)
- Molecular profiling (1)
- Molecular signatures (1)
- Molecular subtype (1)
- Molecular subtypes (1)
- Monosaccharide Transport Proteins (1)
- Monte Carlo simulation (1)
- Morbidity (1)
- Morphogenesis (1)
- Motor control (1)
- Mouse models (1)
- Mucopolysaccharidoses (1)
- Multi-nucleated cardiomyocytes (1)
- Multidrug-resistant tuberculosis (1)
- Multinomial logistic regression (1)
- Multivariable analysis (1)
- NASH (1)
- NCH93 (1)
- NDR1 (1)
- NDUFAF8 (1)
- NEAT1 (1)
- NEAT2 (1)
- NGS (1)
- NK cell (1)
- NK cells (1)
- NK-92 (1)
- NKG2D (1)
- NKT cell (1)
- NMDA IgA/IgM antibodies (1)
- NMDA antibody (1)
- NMDAR subunit GluN2B (1)
- NOTCH1 (1)
- NPSR1 (1)
- NSAIDs (1)
- Nanopore (1)
- Native T1 (1)
- Native T1 mapping (1)
- Nav channel activity (1)
- Nav1.7 (1)
- Neonatal urea cycle disorders (1)
- Neonates (1)
- Network model (1)
- Neuro-ophthalmology (1)
- Neuroimaging (1)
- Neuroscience (1)
- Nivolumab (1)
- Non-REM sleep (1)
- Non-coding RNA (1)
- Non-invasive brain stimulation (1)
- Non-small cell lung cancer (1)
- Nonunion (1)
- Notch (1)
- Nox4 (1)
- Numerical simulation (1)
- OXA-48 (1)
- Occupational medicine (1)
- Olfactory diagnostics (1)
- One health (1)
- Opacity (1)
- Oposterior urethral valve (1)
- Opportunistic infections (1)
- Optical lenses (1)
- Oral Health Impact Profile (OHIP) (1)
- Oral and maxillofacial surgery (1)
- Oral anticoagulation (1)
- Oral implantology (1)
- Oral surgery (1)
- Organ dysfunction (1)
- Oroantral (1)
- Oroantral communication (1)
- Osteogenic differentiation (1)
- Osteoporosis diagnosis (1)
- PCP (1)
- PCSK9 protein (1)
- PEI (1)
- PF-06273340 (1)
- PGE2 (1)
- PID prevalence (1)
- PINK1 (1)
- PKCε (1)
- PLK1 inhibitors (1)
- PPARγ (1)
- Paediatric research (1)
- Pain (1)
- Pancreatic surgery (1)
- Pancreatoduodenectomy (1)
- Panic disorder (1)
- Parapneumonic pleural effusion (1)
- Parkinson disease (1)
- Parkinson’s disease (1)
- Particles (1)
- Pathogenesis (1)
- Pathogenicity (1)
- Patient preferences (1)
- Pause (1)
- Pediatric patients (1)
- Pediatrics (1)
- Pentaglobin (1)
- Peritonitis (1)
- Personalised medicine (1)
- Pharm-fMRI (1)
- Pharmacometrics (1)
- Philadelphia chromosome-positive acute leukemia (1)
- Phylogenetic analysis (1)
- Platelet-rich fibrin (1)
- Platelets (1)
- Platzierung (1)
- Plerixafor (1)
- Pleural empyema (1)
- Pneumocystis jirovecii (1)
- Pneumonia (1)
- Polyunsaturated fatty acids (1)
- Ponatinib (1)
- Portal veins (1)
- Portugal (1)
- Posaconazole serum level (1)
- Positron-emission tomography (1)
- Post treatment (1)
- Precision (1)
- Precision oncology (1)
- Prenatal ultrasonographic detection rate (1)
- Preoperative diagnostics (1)
- Prevalence (1)
- Prevention (1)
- Primary care (1)
- Primary cilium (1)
- Primary health care [MeSH] (1)
- Prisoners (1)
- Prisons (1)
- Profilometry (1)
- Prognostic biomarker (1)
- Prophylaxis (1)
- Prostaglandin (1)
- Prostate-specific membrane antigen (1)
- Prostatic neoplasms (1)
- Protease inhibitor therapy (1)
- Protein translation (1)
- Proteomics (1)
- Proteostasis (1)
- Proton density (1)
- Psychometric evaluation (1)
- Psychometrics (1)
- Quality of care (1)
- Quantitative MRI (1)
- Questionnaires (1)
- REMS (1)
- RNA binding proteins (1)
- RNA extraction (1)
- RNA isolation (1)
- RNAi (1)
- RTS (1)
- RUCAM (1)
- Radiotherapy (1)
- Rare Diseases (1)
- Re-injury (1)
- Reaction time (1)
- Reactive oxygen species (1)
- Real-world evidence (1)
- Recurrence (1)
- Red blood cell transfusion (1)
- Refractory ALL (1)
- Regenerative medicine (1)
- Regression analysis (1)
- Regulatory T cells (1)
- Rehabilitation (1)
- Relapsed ALL (1)
- Relaxometry (1)
- Renal system (1)
- Reproducibility (1)
- Research trends (1)
- Retina (1)
- Retro-IDEAL (1)
- Return to play (1)
- Return to sports (1)
- Rhabdomyosarcoma (1)
- Rheumatoid arthritis (1)
- Rheumatology (1)
- Rho/Rho-kinase (1)
- Ribosomes (1)
- Risk assessment (1)
- Risk prediction (1)
- Roe deer (1)
- Roughness (1)
- Roussel Uclaf Causality Assessment Method (1)
- Roussel Uclaf Causality Assessment Method (RUCAM) (1)
- S1P (1)
- S1PR1 (1)
- SCA34 (1)
- SCA38 (1)
- SHH (1)
- SILAC (1)
- ST2L (1)
- STAT3 (1)
- SUMO1-3 (1)
- SUMOylation (1)
- SUV (1)
- SW480 cells (1)
- SWATH (1)
- Saccades (1)
- Saccadometry (1)
- Safety (1)
- Salivary gland diseases (1)
- Salvage therapy (1)
- Sarcopenia (1)
- Scanner models (1)
- Scedosporium spp. (1)
- Screening (1)
- Screening guidelines (1)
- Secondary prevention (1)
- Seizure (1)
- Sensory perception (1)
- Sensory systems (1)
- Sequence motif analysis (1)
- Serine proteases (1)
- Serotype 3 (1)
- Severe bacterial infection (1)
- Sex differences (1)
- Signal transduction (1)
- Single-cell RNA-sequencing (1)
- Small RNA analysis (1)
- Smooth muscle cells (1)
- Social epidemiology (1)
- Social health determinants (1)
- Social participation (1)
- Somatization (1)
- Specimen preparation and treatment (1)
- Speech signal processing (1)
- Splanchnic Hemodynamics (1)
- Staphylococcus aureus (1)
- Steatosis (1)
- Stem cell (1)
- Stem cells (1)
- Stenosis (1)
- Sterblichkeit (1)
- Steroid (1)
- Streptococcus pneumoniae (1)
- Stress (1)
- Stress and resilience (1)
- Striatum (1)
- Stromal cell (1)
- Structured reporting (1)
- Subarachnoid hemorrhage (1)
- Subcutaneous (1)
- Surface (1)
- Surgical education (1)
- Survival (1)
- Sustained virological response (SVR) (1)
- Systematic reviews (1)
- Systemic lupus erythematosus (1)
- Systems biology (1)
- Systems medicine (1)
- T cell (1)
- T cell receptors (1)
- TBK1 (1)
- TCR signaling cascade (1)
- TEER (1)
- TF-complexes (1)
- TGF-β1 (1)
- TILs (1)
- TIMP2 (1)
- TKI (1)
- TMEM126B (1)
- TMS (1)
- TMT (1)
- TP53-induced glycolysis and apoptosis regulator (1)
- TRIM25 (1)
- Tacrolimus (1)
- Target identification (1)
- Targeted therapies (1)
- Taxane (1)
- Tea (1)
- Telomere length (1)
- Telomeres (1)
- Texture analysis (1)
- Theft (1)
- Therapy (1)
- Therapy response (1)
- Thoracic trauma (1)
- Thromboembolism (1)
- Thrombosis (1)
- Thrombotic microangiopathy (1)
- Thrombotic thrombocytopenic purpura (1)
- Thromboxane (1)
- Thymocytes (1)
- Thymus (1)
- Tick (1)
- Time in therapeutic range (TTR) (1)
- Time to treatment failure (1)
- Tissue microarray (TMA) (1)
- Tools and ressources (1)
- Total hip replacement (1)
- Toxicity (1)
- Transcription Factors (1)
- Transcriptional control (1)
- Transgender (1)
- Translation initiation (1)
- Translational (1)
- Translational research (1)
- Trees (1)
- Treg cell (1)
- Trimeric autotransporter adhesins (1)
- Trk (1)
- TrkC (1)
- Trousseau’s syndrome (1)
- Trueness (1)
- Tularemia (1)
- Tumor heterogeneity (1)
- Tumour immunology (1)
- U-87MG (1)
- Ulcerative colitis (1)
- Ultrasonography (1)
- Ultrasound (1)
- Umbilical cord (1)
- Unilateral hip osteoarthritis (1)
- United States (1)
- Uveal melanoma (1)
- VARGADO (1)
- VDR (1)
- VEGFA (1)
- VGAT-ChR2 (1)
- VISTA (1)
- Vaccination (1)
- Vaccine breakthrough (1)
- Vacuoles (1)
- Validation (1)
- Vascular disease (1)
- Vasculogenesis (1)
- Veins (1)
- Video-oculography (1)
- Viral load (1)
- Virtual implant planning (1)
- Virtual patients (1)
- Virulence (1)
- Visual acuity (1)
- Visual impairments (1)
- Visual system (1)
- Vitamin K antagonists (1)
- Vitreous opacity (1)
- Vmem (1)
- Volume overload (1)
- Voriconazole (1)
- WNT (1)
- WT1 (1)
- Westphal-Paradigm (1)
- White blood cells (1)
- WoMo score (1)
- Working memory (1)
- Wound healing (1)
- Zebrafish (1)
- Zika virus (1)
- Zoonosis (1)
- abuse (1)
- accidents (1)
- acid sphingomyelinase (ASMase; Smpd1) (1)
- acneiform skin toxicity (1)
- acoustic radiation force impulse imaging (1)
- acute decompensation (1)
- acute liver failure (1)
- acute lung injury (1)
- acute lung injury (ALI) (1)
- acute-on-chronic liver failure (1)
- adalimumab (1)
- adeno-associated virus (1)
- adeno‐associated virus (1)
- adherence (1)
- adhesion (1)
- adipocytes (1)
- adiponectin (1)
- adipose tissue (1)
- adipose-derived mesenchymal stem cells (1)
- adipose-derived stem cells (1)
- adolescents (1)
- adoptive cancer immunotherapy (1)
- adrenal insuffciency (1)
- adult attention deficit/hyperactivity disorder (adult ADHD) (1)
- adverse effects (1)
- ageing (1)
- aging (1)
- air flow (1)
- air pollution (1)
- airborne bacteria (1)
- albumin (1)
- alcohol (1)
- alcohol dehydrogenase (ADH) (1)
- alcohol metabolism (1)
- alcoholic liver disease (1)
- alcoholic liver injury (1)
- alloHSCT (1)
- allogeneic stem cell transplantation (1)
- alpha receptor (1)
- alpha-synuclein (1)
- amisulpride (1)
- amyotrophic lateral sclerosis (ALS) (1)
- anaemia (1)
- anal cancer (1)
- anaplastic large cell lymphoma (1)
- angio-immunogenic switch (1)
- animal models (1)
- anti-cancer therapy (1)
- antibodies (1)
- anticonvulsant (1)
- antiepileptic drug (1)
- antifibrotic therapy (1)
- antifungal therapy (1)
- antisynthetase antibodies (1)
- antisynthetase syndrome (1)
- antiviral drugs (1)
- apigenin (1)
- aromatics (1)
- arthritis (1)
- artificial intelligence (1)
- ascites (1)
- associative memory (1)
- astrocytoma (1)
- ataxia score (1)
- ataxia telangiectasia (1)
- atherosclerosis (1)
- atrial fibrillation (1)
- attention modulation (1)
- attention-deficit/hyperactivity disorder (1)
- attention-deficit/hyperactivitydisorder (1)
- attractiveness (1)
- augmentation (1)
- authentication (1)
- autism spectrum disorder (1)
- autologous stem cell transplantation (1)
- automated patch-clamp (1)
- azaindole (1)
- bacteria (1)
- basic mechanisms (1)
- basonuclin 2 (1)
- beam quality correction factors (1)
- belimumab (1)
- beta‐trace protein (1)
- bevacizumab (1)
- binary search procedure (1)
- bioacoustics (1)
- bioactivity (1)
- biofilm (1)
- biological treatments (1)
- biologics (1)
- biomarkers (1)
- biopsy (1)
- bipolar disorder (1)
- bladder cancer (1)
- bladder dose (1)
- blood flow restriction (1)
- bmal1 (1)
- body mass index (1)
- bone chips (1)
- bone damage (1)
- bone healing (1)
- bone loss (1)
- bone marrow derived mononuclear cells (1)
- bone morphogenetic proteins (BMPs) (1)
- bone regeneration (1)
- bone‐screw (1)
- bone–implant interface (1)
- borrelia (1)
- borrelia mayonii (1)
- brachytherapy (1)
- brain phosphorylome (1)
- brain states (1)
- bronchial allergen provocation (1)
- cadherin (1)
- calcitriol (1)
- callous-unemotional traits (1)
- calprotectin (1)
- calretinin (1)
- calretinin-knock out (1)
- cancer cell metabolism (1)
- cancer patients (1)
- cancer stem cells (1)
- cancer treatment (1)
- cancer-associated fibroblasts (1)
- cancer-specific survival (1)
- cannabis (1)
- cap-dependent translation (1)
- capsaicin (1)
- car indoor (1)
- carbapenemases (1)
- carbon oxides (COx) (1)
- cardiac myocytes (1)
- cardiomegaly (1)
- cardiovascular (1)
- cardiovascular management (1)
- case reports (1)
- caspase 8 (1)
- caspase-8 (1)
- catheter removal (1)
- cdk (1)
- cell adhesion (1)
- cell biology (1)
- cell cycle arrest (1)
- cell cycling (1)
- cell death (1)
- cell growth (1)
- cell line (1)
- cell motility (1)
- cell survival mechanisms (1)
- cell therapy (1)
- centrifugation (1)
- ceramide (1)
- ceramide synthase (CERS2/CERS1) (1)
- cerebral radiation necrosis (1)
- cerebrovascular disease (1)
- ceritinib (1)
- cervical cancer (1)
- channelrhodopsin (1)
- characterization (1)
- checkpoint proteins (1)
- chemokine receptors (1)
- chemoradiotherapy (1)
- chemoresistance (1)
- chemotherapy (1)
- chemotherapy resistance (1)
- chest injury (1)
- chest trauma (1)
- child (1)
- childhood abuse (1)
- children (1)
- chimeric antigen receptor (1)
- chronic myeloid leukemia (1)
- chronobiology (1)
- cigarette strength (1)
- cigarettes (1)
- circadian rhythm (1)
- circulating miRNA (1)
- classical conditioning (1)
- classification of bone defects (1)
- clinical immunology (1)
- clinical research (1)
- clinical study (1)
- clinical trial (1)
- cloacae (1)
- clock genes (1)
- clonal dominance (1)
- clonal hematopoiesis (1)
- cochlear implant (1)
- cognitive deficits (1)
- cognitive functions (1)
- collagen (1)
- collagen I (1)
- collagen degradation marker (1)
- collateral sprouting (1)
- colon carcinoma cells (1)
- colorectal carcinoma (1)
- combination treatment (1)
- common variant (1)
- complex I (1)
- complex I deficiency (1)
- compliance (1)
- computational models (1)
- computational neuroscience (1)
- computational techniques (1)
- computational virology (1)
- concordance (1)
- conduct disorder (1)
- connective tissue graft (1)
- consensus paper (1)
- convolution neural network (1)
- coordination (1)
- copeptin (1)
- cornea donor (1)
- coronary artery bypass graft surgery (1)
- cortical malformation (1)
- cortical thickness (1)
- cortisol (1)
- cost-effective (1)
- courting behavior (1)
- critical size defect (1)
- critically ill patients (1)
- cross-sectional study (1)
- cryopreservation (1)
- cyclin D1 (1)
- cyclins (1)
- cyclosporine (1)
- cystatin C (1)
- cystic fibrosis (1)
- cytochrome P450 2E1 (1)
- cytokine, angiogenesis (1)
- cytotoxic T cells (1)
- death (1)
- death receptor (1)
- deep neural network (1)
- defect configuration (1)
- delayed wound healing (1)
- dental implants (1)
- depression (1)
- depressive symptoms (1)
- desmoplastic small round cell tumor (1)
- detoxification (1)
- diabetic neuropathy (1)
- diffusion tensor imaging (1)
- diffusion tensor imaging (DTI) (1)
- dimethylfumarate (1)
- direct-acting antivirals (DAAs) (1)
- directed disulfide bond formation (1)
- discoidin domain-containing receptor (1)
- discomfort/pain (1)
- disease-free survival (1)
- dissemination (1)
- distal pronephric outlet obstruction (1)
- distress (1)
- docetaxel (1)
- dopamine (1)
- dosimetry (1)
- double inversion recovery (DIR) (1)
- doxorubicin (1)
- drilling tool design (1)
- drug induced liver injury (1)
- drug metabolism and distribution (1)
- drug release (1)
- drug resistance (1)
- drug targets (1)
- drug therapy (1)
- drug-induced liver injury (1)
- drug-induced liver injury (DILI) (1)
- dual task (1)
- dynamic 18F-FDG PET/CT (1)
- early continence (1)
- early loss (1)
- early tumor stages (1)
- economy (1)
- edema (1)
- ejection fraction (EF) (1)
- elderly patients (1)
- electrical stimulation (1)
- electrocardiography (1)
- electron transport chain (1)
- eltrombopag (1)
- emergency care (1)
- emergent self-organizing maps (1)
- emotional information processing (1)
- empowerment (1)
- endometriosis (1)
- endophytes (1)
- endoplasmic reticulum (1)
- endothelial cell (1)
- endothelial cells (1)
- endothelial to mesenchymal transition (1)
- endotoxins (1)
- entorhinal cortex lesion (1)
- envelope technique (1)
- eosinophil cationic protein (1)
- eosinophils (1)
- epigenetic (1)
- epigenetics (1)
- epigenome (1)
- euthymic (1)
- evaluation (1)
- evaluation practice (1)
- everolimus (1)
- evoked response (1)
- evolution (1)
- ex vivo expansion (1)
- excess fluid volume (1)
- executive function (1)
- exercise training (1)
- exosomes (1)
- expression studies (1)
- extracellular vesicles (1)
- eye tracking (1)
- face-name association task (1)
- factor H (1)
- factor IX (1)
- factor VIII (1)
- fat (1)
- fatty acid elongase (Elovl1/4/5) (1)
- fatty acids (1)
- feedback (1)
- femoral artery ligation (1)
- fibroblasts (1)
- fibrocytes (1)
- fibrosis (1)
- fibrotest (1)
- fidaxomicin (1)
- fitness (1)
- fixed partial dentures (1)
- fizička aktivnost; (1)
- flavivirus entry factor (1)
- flow cytometry (1)
- fluorescent dye (1)
- focal adhesion (1)
- focal cortical dysplasia (FCD) (1)
- fresh frozen plasma (1)
- full-contour crown restorations (1)
- functional connectivity (1)
- functional genetics (1)
- fungal pathogens (1)
- fungi (1)
- fusion (1)
- gRNA library (1)
- gadolinium‐based contrast agent (1)
- gel spacer injection (1)
- gender (1)
- gender dysphoria (1)
- gender-affirming hormone therapy (1)
- gene expression (1)
- gene expression analysis (1)
- gene regulation (1)
- gene signature (1)
- gene therapy (1)
- genetics (1)
- genetics and genomics (1)
- gene×environment interactions (1)
- genome-wide (1)
- glecaprevir (1)
- glial activation (1)
- glioblastoma (GBM) (1)
- global diversity (1)
- glutamate (1)
- glutamine (1)
- gossypol (1)
- graft-versus host (1)
- granulocytecolony stimulating factor (1)
- granuloma (1)
- gray‐white matter blurring (1)
- growth (1)
- growth hormone (1)
- growth inhibition (1)
- gut microbiota (1)
- haemophilia (1)
- head and neck cancer (1)
- head-to-head (1)
- health apps (1)
- health‐related quality of life (1)
- heart (1)
- heart rate (1)
- heat (1)
- hematopoiesis (1)
- hematopoietic stem cell mobilization (1)
- hematopoietic stem cells (1)
- hematopoietic stress (1)
- hepatic osteodystrophy (1)
- hepatic phenotype (1)
- hepatic steatosis (1)
- hepatitis B (1)
- hepatitis B virus (1)
- hepatitis C virus (HCV) (1)
- herb induced liver injury (1)
- hereditary angioedema (1)
- high molecular weight plasticizer (1)
- high-dimensional data sets (1)
- high-dose-rate interstitial brachytherapy (1)
- high-energy photon and proton radiation (1)
- hippocampus (1)
- histone deacetylases (HDACs) (1)
- hospital exemption (1)
- host cell interaction (1)
- host cell response (1)
- host immune response (1)
- host-directed therapies (1)
- hostpathogen interaction (1)
- human Natural Killer cell (1)
- human antigen R (HuR) (1)
- human biology and medicine (1)
- human cytomegalovirus (1)
- human immunodeficiency virus (1)
- human skin graft (1)
- humectant agents (1)
- hygienic hand disinfection (1)
- hygienische Händedesinfektion (1)
- hypertension and anti-hypertensive treatment (1)
- hypoparathyroidism (1)
- hypoxia-inducible factor (1)
- idiopathic dystonia (1)
- idiopathic pulmonary fibrosis (1)
- idiosyncratic DILI (1)
- ifenprodil (1)
- illness experiences (1)
- image analysis (1)
- immune deficiency (1)
- immune dysregulation (1)
- immune landscape (1)
- immune responses (1)
- immune system (1)
- immune-checkpoint inhibition (1)
- immunity (1)
- immunoglobulin superfamily (1)
- immunological research (1)
- immunology and infectious diseases (1)
- immunosuppressive agent (1)
- immunosuppressive drug (1)
- implant movement (1)
- implant stability (1)
- in silico simulation (1)
- in vivo micro‐CT (1)
- indication (1)
- indomethacin (1)
- induced membrane (1)
- infiltration (1)
- inflammatory bowel disease (1)
- information transfer (1)
- inhibitory interneurons (1)
- insect herbivory (1)
- insertion (1)
- insula (1)
- integrated stress response (1)
- intensive care unit (1)
- interferon gamma (1)
- internal ribosomal entry site (IRES) (1)
- interstitial lung disease (1)
- intestinal barrier (1)
- intrinsic DILI (1)
- intrinsic apoptosis (1)
- invasive fungal disease (1)
- ionotropic glutamate receptors (1)
- iron chelation (1)
- iron chelator (1)
- iron chelators (1)
- iron deficiency (1)
- iron homeostasis (1)
- iron metabolism (1)
- irradiation (1)
- isogenic (1)
- ixekizumab (1)
- junctional adhesion molecule (1)
- juvenile myoclonic epilepsy (1)
- kidney transplantation (1)
- kinesin (1)
- lapatinib (1)
- latent tuberculosis infection (1)
- left ventricular function (1)
- legal gender reassignment (1)
- leukocytes (1)
- leukodystrophy (1)
- lifelong learning (1)
- light transmission aggregometry (1)
- liminality (1)
- linoleic acid metabolites (1)
- lipid mediator (1)
- lipid metabolism (1)
- lipids (1)
- lipids inflammatory pain (1)
- lipocalin-2 (1)
- lipopolyplex (1)
- lipopolysaccharide (1)
- lipoxygenase (1)
- liquid-PRF (1)
- liver (1)
- liver adaption (1)
- liver cancer (1)
- liver cell lines (1)
- liver diseases (1)
- liver fibrosis (1)
- liver injury (1)
- liver metabolism (1)
- local control (1)
- long-term distress (1)
- longitudinal relaxation time T1 (1)
- low speed centrifugation concept (1)
- low-back pain (1)
- low-cost medication (1)
- lower urinary tract obstruction (1)
- luteolin (1)
- lyme disease (1)
- lymphangiogenesis (1)
- mGluR3 (1)
- mGluR5 (1)
- mRNA active cancer immunotherapy (1)
- mRNA decay (1)
- mRNA stability (1)
- mTOR inhibition (1)
- mTORC1 (1)
- machine learning (1)
- machine-learning (1)
- maintenance therapy (1)
- major adverse cardiac events (1)
- major depressive disorder (1)
- malignant glioma (1)
- mammary cancer (1)
- mammary carcinoma (1)
- marathon (1)
- maraton (1)
- mass spectrometry (1)
- massive weight loss (1)
- massively parallel multigrid solvers (1)
- mathematical models of viral RNA cycle (1)
- matrix metalloproteinase (1)
- mechanistic target of rapamycin (mTOR) (1)
- medial thigh lift (1)
- medical error (1)
- medulloblastoma resection (1)
- memantine (1)
- memory (1)
- meningioma (1)
- merkel cell carcinoma (1)
- mesenchymal stromal cell (1)
- mesenchymal stromal/stem cells (1)
- metabolites (1)
- metastasis (1)
- metastates (1)
- metformin (1)
- methylation profiling (1)
- miR (1)
- miR-143-3p (1)
- miR-181 (1)
- miR-375 (1)
- mice (1)
- microbiome (1)
- microdosing (1)
- microglia (1)
- microsomal ethanol-oxidizing system (MEOS) (1)
- microtubular cytoskeleton (1)
- microtubule disruptors (1)
- mild cognitive impairment (1)
- mitochondrial bioenergetics and glycolysis (1)
- mitochondrial disease (1)
- mitophagy (1)
- mobile phone apps (1)
- mobile tongue cancer (1)
- modeling (1)
- molecular diagnosis (1)
- molecular marker (1)
- montelukast (1)
- motility (1)
- mouse (1)
- mouse model (1)
- movement disorders (1)
- mpMRI (1)
- mtor (1)
- mucosal inflammation (1)
- mucositis (1)
- multidisciplinary pain treatment (1)
- multimorbidity (1)
- multiplex immunofluorescence (1)
- musician (1)
- mutations (1)
- mycophenolate mofetil [MMF] (1)
- myeloid cells (1)
- myocardial infarction (1)
- myocardial injury (1)
- myocardium (1)
- myogenic tone (1)
- myogenic vasoconstriction (1)
- myositis (1)
- nadp (1)
- nanoparticles (1)
- natural killer cells (1)
- nematophin (1)
- neoplasms (1)
- nerve-sparing (1)
- network analysis (1)
- network neuroscience (1)
- neural network (1)
- neuroblastoma (1)
- neurodegeneration (1)
- neurodevelopmental disorders (1)
- neuronal silencing (1)
- neurons (1)
- neuropathic pain (1)
- neuropsychological impairment (1)
- neurotrophins (1)
- neutral ceramidase (Asah2) (1)
- neutral sphingomyelinase (Smpd3) (1)
- new miRNA functions (1)
- nintedanib (1)
- nitrogen oxides (NOx) (1)
- nocardia (1)
- nocardiosis (1)
- nodular sclerosis (1)
- non-classical adhesion molecule (1)
- non-invasive fibrosis assessment (1)
- non-sensory bias (1)
- non-small-cell lung cancer (1)
- noradrenaline (1)
- norepinephrine (1)
- nutrient deprivation (1)
- observational cohort study (1)
- oksidacioni stres (1)
- older patients (1)
- olivo-ponto-cerebellar atrophy (OPCA) (1)
- oncogene (1)
- oncolytic virotherapy (1)
- optogenetics (1)
- organ dysfunction (1)
- organ failure (1)
- organisation of health services (1)
- organophosphate flame retardants (OFR) (1)
- orthodontic mini‐implant (1)
- oscillator (1)
- osteoarthritis (1)
- osteogenesis (1)
- osteopenia (1)
- osteotomy (1)
- outcome (1)
- overall survival (1)
- overweight (1)
- oxidative stress (1)
- p14 (1)
- p62 (1)
- p75 (1)
- pack-years (PY) (1)
- pain (1)
- pain management (1)
- pain target (1)
- palatal tremor (1)
- particulate matter (PM) (1)
- passive reading paradigm (1)
- patent (1)
- patient (1)
- patient and public involvement (1)
- patient blood management (1)
- patient perspective (1)
- patient preference (1)
- patient safety (1)
- patients' experience (1)
- patient‐centred outcomes (1)
- pazopanib (1)
- pediatric patients (1)
- pedicle screws (1)
- peficitinib (1)
- perforant path transection (1)
- performance evaluation (1)
- performance-based funding allocation (1)
- perio-prosthetic joint infection (1)
- periodontal probing, (1)
- periodontitis (1)
- perirenal (1)
- peri‐implant lesions (1)
- peri‐implant probing (1)
- peri‐implantitis (1)
- pharmaco-fMRI (1)
- pharmacodynamics (1)
- pharmacogenetics (1)
- pharmacoresistance (1)
- phase 3 study (1)
- phosphatases (1)
- phylogenetic analysis (1)
- physical activity (1)
- pibrentasvir (1)
- pitch perception (1)
- placement (1)
- plant growth (1)
- plant resistance (1)
- plant-insect interactions (1)
- plasmid (1)
- plastic (1)
- plasticity (1)
- platelet aggregation (1)
- platelet lysate (1)
- platelet rich plasma (1)
- platelet-rich fibrin (1)
- platelets (1)
- platform switching (1)
- pleuropericarditis (1)
- point shear wave elastography (1)
- polo-like kinase 1 (1)
- polo-like kinase 3 (1)
- poly(lactic-co-glycolic acid) (PLGA) (1)
- polyethylenimine (1)
- polyomavirus (MCPyV) (1)
- polypharmacology (1)
- population dynamics (1)
- post-translational modifications (PTMs) (1)
- posterior fossa masses (1)
- postmortem blood samples (1)
- posttraumatic stress disorder (1)
- post‐traumatic stress disorder (1)
- power dynamics (1)
- pranlukast (1)
- pre-clinical models (1)
- preeclampsia (1)
- prefrontal cortex (1)
- preoperative anaemia management (1)
- pressure cycling technology (1)
- pressure ulcer treatment (1)
- preterm birth (1)
- primary cilium (1)
- primary immunodeficiency (1)
- primary immunodeficiency (PID) (1)
- progestin (1)
- prognosis (1)
- progressive myoclonus epilepsy (1)
- pronephric development (1)
- prophylaxis (1)
- prospective studies (1)
- protein tagging (1)
- proto-oncogene proteins c-akt (1)
- proton density (1)
- proton pump inhibitors (1)
- psoriatic arthritis (1)
- psychological distress (1)
- psychophysiology (1)
- psychosocial stress (1)
- public health (1)
- pulmonary nocardiosis (1)
- pulse labeling (1)
- pulse-spreading harmonic complex (1)
- pupil dilation (1)
- pupillary reactivity (1)
- qualitative research (1)
- quality assurance (1)
- quantitative T1 mapping (1)
- quantitative T1‐difference maps (1)
- radiation therapy (1)
- radioimmunotherpay (1)
- radioresponse (1)
- radixin (1)
- randomized (1)
- rare variant (1)
- re-emerging virus (1)
- re-osseointegration (1)
- reactivation (1)
- reactive oxygen species (ROS) (1)
- reaktivne vrste kiseonika (1)
- real-world data (1)
- realistic geometries (1)
- recertification (1)
- recommendations (1)
- recurrent laryngeal nerve palsy (1)
- refractory aGvHD (1)
- regeneration (1)
- registry for primary immunodeficiency (1)
- regorafenib (1)
- regorafenib csf concentration (1)
- relaxometry (1)
- remote monitoring (1)
- removal (1)
- renal cell cancer (1)
- renin-angiotensin system (1)
- reorganization (1)
- repeat DMEK (1)
- reservoir computing (1)
- resistance (1)
- resistance-associated substitutions (RAS) (1)
- resting-state fMRI (1)
- resting‐state (1)
- retrospective (1)
- revalidation (1)
- revision surgery (1)
- rhabdomyosarcoma (1)
- rhabdomyosarcomas (1)
- rheumatoid arthritis (1)
- ribavirin (1)
- right ventricular function (1)
- risk factor progression (1)
- risk genes (1)
- risk management (1)
- root coverage (1)
- rosetting T cells (1)
- rub-in technique (1)
- running wheel (1)
- sRNA (1)
- sRNA tool (1)
- safety (1)
- scaffold size (1)
- schizophrenia (1)
- schizophrenia spectrum (1)
- sclerostin (1)
- scoping review (1)
- screening test (1)
- screw augmentation (1)
- screw loosening (1)
- second-hand smoke (1)
- secretion (1)
- seed germination (1)
- segmentation (1)
- seizure (1)
- selectin (1)
- sensorimotor exercise training (1)
- sensory neuropathy (1)
- sensory processing (1)
- serine palmitoyltransferase 2 (Sptlc2) (1)
- serologic screening (1)
- serositis (1)
- serum albumin deficiency (1)
- severe vitamin D deficiency (1)
- sex differences (1)
- sexually transmitted diseases (1)
- sexually transmitted infection (1)
- sham (1)
- shortening of treatment (1)
- shunt (1)
- siRNA analysis (1)
- siRNA delivery (1)
- siRNA quantification (1)
- siRNA/RNAi (1)
- signature (1)
- silicone device (1)
- simulation (1)
- simulation training (1)
- single-sided deafness (1)
- sinus rhythm (1)
- six-step technique (1)
- smoking (1)
- sofosbuvir (1)
- soft tissue sarcoma (1)
- soft tissue sarcoma (STS) (1)
- soluble epoxide hydrolase (1)
- somatic mutations (1)
- sonic hedgehog signaling (1)
- sound-induced flash illusion (1)
- spatial specificity (1)
- spectroscopy (1)
- sphingolipid (1)
- spider toxin (1)
- spiking neural networks (1)
- spinal fusion (1)
- spirochete (1)
- spirochetes (1)
- starvation (1)
- stem cell transplantation (1)
- steroid-resistant aGvHD (1)
- stimulation (1)
- stopping rule (1)
- stratification (1)
- strength training (1)
- stress response (1)
- stroke (1)
- structural covariance (1)
- subcutaneous fat (1)
- subjunctivity (1)
- success rate (1)
- sulfasalazine (1)
- suplementacija (1)
- supplementation (1)
- support vector machines (1)
- surveillance (1)
- survival (1)
- survival rate (1)
- synaptic signaling (1)
- synovial fibroblast (1)
- systemic inflammation (1)
- t-distributed stochastic neighbor embedding (1)
- tDCS (1)
- tacrolimus (1)
- target variability (1)
- telemedicine (1)
- telmisartan (1)
- temozolomide (1)
- temsirolimus (1)
- temsirolimus-resistance (1)
- thighplasty (1)
- thrombocyte dysfunction (1)
- thrombocyte function (1)
- thrombolysis (tPA) (1)
- thrombopietin receptor agonist (1)
- thrombospondin-4 (1)
- thymus (1)
- thyroid resection (1)
- tissue Doppler imaging (1)
- tissue engineering (1)
- tolerance (1)
- tongue edema (1)
- topographic maps (1)
- total joint arthroplasty (TJA) (1)
- trafficking (1)
- transcriptional profiling (1)
- transcriptome (1)
- transdifferentiation (1)
- transforming growth factor beta (1)
- transforming growth factor beta (TGF-β) (1)
- transient elastography (1)
- transient receptor potential channels (1)
- translation (1)
- transmission and vector control (1)
- transsexualism (1)
- trastuzumab (1)
- trophoblastic cell lines (1)
- trophoblasts (1)
- troponin (1)
- tumor (1)
- tumor growth (1)
- tumor immune evasion (1)
- tumor microenviroment (1)
- tumor progression (1)
- tumor proliferation (1)
- tumor‐associated macrophages (1)
- two-tissue compartment model (1)
- tyrosine kinase inhibitor (1)
- ulcerative colitis (1)
- uncertainty (1)
- unfolded protein response (1)
- ustekinumab (1)
- uterine cervical cancer (1)
- vaccine (1)
- valproic acid (1)
- vancomycin (1)
- vascular complications (1)
- vascular disease (1)
- vascular dysfunction and inflammation (1)
- vascular smooth muscle (1)
- velpatasvir (1)
- ventral tegmental area (1)
- vesicovaginal septum (1)
- viability (1)
- viral dynamics (1)
- viral gene transfer (1)
- virulence (1)
- vitamin D supplementation (1)
- vitamin D target genes (1)
- vitamin Dmetabolism (1)
- voice (1)
- volatile organic compounds (VOC) (1)
- voluntary training (1)
- voxilaprevir (1)
- within-host viral modeling (1)
- women (1)
- words (1)
- work-life balance (1)
- working conditions (1)
- wound healing (1)
- yellow fever virus (1)
- yellow fever virus tropism (1)
- zafirlukast (1)
- zebrafish (1)
- zirconia (1)
- Überwachung (1)
- β-catenin (1)
- β-lactamases (1)
- γδT cell (1)
- гепатит С (1)
- правила прекращения лечения (1)
- противовирусные препараты прямого действия (ПППД) (1)
- сокращение лечения (1)
- устойчивый вирусологический ответ (УВО) (1)
- flow cytometry (1)
Institute
- Medizin (500) (remove)
Malignant germ cell tumors (GCT) are the most common malignant tumors in young men between 18 and 40 years. The correct identification of histological subtypes, in difficult cases supported by immunohistochemistry, is essential for therapeutic management. Furthermore, biomarkers may help to understand pathophysiological processes in these tumor types. Two GCT cell lines, TCam-2 with seminoma-like characteristics, and NTERA-2, an embryonal carcinoma-like cell line, were compared by a quantitative proteomic approach using high-resolution mass spectrometry (MS) in combination with stable isotope labelling by amino acid in cell culture (SILAC). We were able to identify 4856 proteins and quantify the expression of 3936. 347 were significantly differentially expressed between the two cell lines. For further validation, CD81, CBX-3, PHF6, and ENSA were analyzed by western blot analysis. The results confirmed the MS results. Immunohistochemical analysis on 59 formalin-fixed and paraffin-embedded (FFPE) normal and GCT tissue samples (normal testis, GCNIS, seminomas, and embryonal carcinomas) of these proteins demonstrated the ability to distinguish different GCT subtypes, especially seminomas and embryonal carcinomas. In addition, siRNA-mediated knockdown of these proteins resulted in an antiproliferative effect in TCam-2, NTERA-2, and an additional embryonal carcinoma-like cell line, NCCIT. In summary, this study represents a proteomic resource for the discrimination of malignant germ cell tumor subtypes and the observed antiproliferative effect after knockdown of selected proteins paves the way for the identification of new potential drug targets.
Exercise is a treatment option in peripheral artery disease (PAD) patients to improve their clinical trajectory, at least in part induced by collateral growth. The ligation of the femoral artery (FAL) in mice is an established model to induce arteriogenesis. We intended to develop an animal model to stimulate collateral growth in mice through exercise. The training intensity assessment consisted of comparing two different training regimens in C57BL/6 mice, a treadmill implementing forced exercise and a free-to-access voluntary running wheel. The mice in the latter group covered a much greater distance than the former pre- and postoperatively. C57BL/6 mice and hypercholesterolemic ApoE-deficient (ApoE-/-) mice were subjected to FAL and had either access to a running wheel or were kept in motion-restricting cages (control) and hind limb perfusion was measured pre- and postoperatively at various times. Perfusion recovery in C57BL/6 mice was similar between the groups. In contrast, ApoE-/- mice showed significant differences between training and control 7 d postoperatively with a significant increase in pericollateral macrophages while the collateral diameter did not differ between training and control groups 21 d after surgery. ApoE-/- mice with running wheel training is a suitable model to simulate exercise induced collateral growth in PAD. This experimental set-up may provide a model for investigating molecular training effects.
Background & Aims: Adequate adherence to hepatitis C virus (HCV) treatment is believed to be a key component of treatment success because non‐adherence can potentially result in treatment failure and the emergence of resistant viral variants. This analysis assessed factors associated with non‐adherence to glecaprevir/pibrentasvir (G/P) therapy and the impact of non‐adherence on sustained virological response at post‐treatment week 12 (SVR12) rates in HCV genotype (GT) 1‐6‐infected patients.
Methods: Adherence was calculated by pill counts at study visits during treatment, and defined as having a lowest treatment adherence of ≥80% and ≤120% at each study visit. Exploratory logistic regression modelling assessed predictors of non‐adherence to G/P therapy. SVR12 rates by treatment adherence were assessed in the intent‐to‐treat (ITT) population and modified ITT (mITT) population, which excludes non‐virological failures.
Results: Overall, 97% (2024/2091) of patients were adherent to G/P therapy at all consecutive study visits. Alcohol use was the only baseline characteristic independently associated with non‐adherence to G/P therapy (OR: 2.38; 95% CI: 1.13‐5.01; P = .022). In the mITT population, overall SVR12 rates were high both in patients who were adherent to G/P therapy and those who were not (99% [1983/2008] and 95% [58/61] respectively; P = .047). Corresponding SVR12 rates in the ITT population were 98% (1983/2024) and 87% (58/67) respectively.
Conclusions: Most patients adhered to G/P therapy. SVR12 rates were high both in patients who were adherent to G/P treatment and those who were not. Patient education on treatment adherence should remain an important part of HCV treatment.
Clinical trials registration: NCT02604017, NCT02640482, NCT02640157, NCT02636595, NCT02642432, NCT02651194, NCT02243293, NCT02446717.
Glioblastoma (GB) is the most common and aggressive primary brain tumor in adults and currently incurable. Despite multimodal treatment regimens, median survival in unselected patient cohorts is <1 year, and recurrence remains almost inevitable. Escape from immune surveillance is thought to contribute to the development and progression of GB. While GB tumors are frequently infiltrated by natural killer (NK) cells, these are actively suppressed by the GB cells and the GB tumor microenvironment. Nevertheless, ex vivo activation with cytokines can restore cytolytic activity of NK cells against GB, indicating that NK cells have potential for adoptive immunotherapy of GB if potent cytotoxicity can be maintained in vivo. NK cells contribute to cancer immune surveillance not only by their direct natural cytotoxicity which is triggered rapidly upon stimulation through germline-encoded cell surface receptors, but also by modulating T-cell mediated antitumor immune responses through maintaining the quality of dendritic cells and enhancing the presentation of tumor antigens. Furthermore, similar to T cells, specific recognition and elimination of cancer cells by NK cells can be markedly enhanced through expression of chimeric antigen receptors (CARs), which provides an opportunity to generate NK-cell therapeutics of defined specificity for cancer immunotherapy. Here, we discuss effects of the GB tumor microenvironment on NK-cell functionality, summarize early treatment attempts with ex vivo activated NK cells, and describe relevant CAR target antigens validated with CAR-T cells. We then outline preclinical approaches that employ CAR-NK cells for GB immunotherapy, and give an overview on the ongoing clinical development of ErbB2 (HER2)-specific CAR-NK cells currently applied in a phase I clinical trial in glioblastoma patients.
Background: Idiopathic pulmonary fibrosis (IPF) is a disease with high 5-year mortality and few therapeutic options. Prostaglandin (PG) E2 exhibits antifibrotic properties and is reduced in bronchoalveolar lavage from patients with IPF. 15-Prostaglandin dehydrogenase (15-PGDH) is the key enzyme in PGE2 metabolism under the control of TGF-β and microRNA 218.
Objective: We sought to investigate the expression of 15-PGDH in IPF and the therapeutic potential of a specific inhibitor of this enzyme in a mouse model and human tissue.
Methods: In vitro studies, including fibrocyte differentiation, regulation of 15-PGDH, RT-PCR, and Western blot, were performed using peripheral blood from healthy donors and patients with IPF and A549 cells. Immunohistochemistry, immunofluorescence, 15-PGDH activity assays, and in situ hybridization as well as ex vivo IPF tissue culture experiments were done using healthy donor and IPF lungs. Therapeutic effects of 15-PGDH inhibition were studied in the bleomycin mouse model of pulmonary fibrosis.
Results: We demonstrate that 15-PGDH shows areas of increased expression in patients with IPF. Inhibition of this enzyme increases PGE2 levels and reduces collagen production in IPF precision cut lung slices and in the bleomycin model. Inhibitor-treated mice show amelioration of lung function, decreased alveolar epithelial cell apoptosis, and fibroblast proliferation. Pulmonary fibrocyte accumulation is also decreased by inhibitor treatment in mice, similar to PGE2 that inhibits fibrocyte differentiation from blood of healthy donors and patients with IPF. Finally, microRNA 218-5p, which is downregulated in patients with IPF, suppressed 15-PGDH expression in vivo and in vitro.
Conclusions: These findings highlight the role of 15-PGDH in IPF and suggest 15-PGDH inhibition as a promising therapeutic approach.
Background: With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clinical practice. This study primarily aimed to describe the time to treatment failure (TTF) of mCRPC patients treated with abiraterone acetate plus prednisone or the corticosteroid of choice (AAP) in the pre-chemotherapy setting. Other relevant outcomes, clinical and treatment characteristics of these patients were also evaluated.
Methods: This retrospective, observational study collected data from chemotherapy-naïve mCRPC patients treated with AAP from four European countries. Kaplan-Meier curves were used to estimate TTF, progression-free survival (PFS), and time to first skeletal-related event. The impact of baseline characteristics on TTF and PFS was explored using univariate and multivariate Cox proportional hazard models. Log-rank test was used to assess the potential role of duration of response to ADT in predicting response to AAP treatment.
Results: Data from 481 eligible patients (Belgium: 68; France: 61; Germany: 150; UK: 202) were analysed. At AAP initiation, the median age of patients was 75.0 years (interquartile range [IQR]: 69.0–81.0), and the median PSA was 56.2 ng/mL (IQR: 22.2–133.1), with over 50% of patients presenting an ECOG score of 0 or 1. Visceral metastases were present in 7.5% of patients; an exclusion criterion in the COU-AA-302 clinical trial. The median TTF with AAP was 10.0 months (95%CI: 9.2–11.1) and the median PFS was 10.8 months (95%CI: 9.6–11.8). Shorter TTF was significantly associated with higher ALP (> 119 units/L), higher PSA (> 56.2 ng/mL), or poorer ECOG PS scores at AAP initiation (p < 0.05). Patients with longer duration of response to ADT (≥12 months) presented longer TTF and longer time to progression (p < 0.0001).
Conclusions: This European real-world study provides valuable insights into the characteristics, treatment, and outcomes of chemotherapy-naïve patients with mCRPC who received AAP in routine clinical practice. Treatment effectiveness of AAP in the real-world is maintained despite patients having poorer clinical features at initiation than those observed in the COU-AA-302 trial population.
(1) Background: Refractory acute graft-versus-host disease (R-aGvHD) remains a leading cause of death after allogeneic stem cell transplantation. Survival rates of 15% after four years are currently achieved; deaths are only in part due to aGvHD itself, but mostly due to adverse effects of R-aGvHD treatment with immunosuppressive agents as these predispose patients to opportunistic infections and loss of graft-versus-leukemia surveillance resulting in relapse. Mesenchymal stromal cells (MSC) from different tissues and those generated by various protocols have been proposed as a remedy for R-aGvHD but the enthusiasm raised by initial reports has not been ubiquitously reproduced.
(2) Methods: We previously reported on a unique MSC product, which was generated from pooled bone marrow mononuclear cells of multiple third-party donors. The products showed dose-to-dose equipotency and greater immunosuppressive capacity than individually expanded MSCs from the same donors. This product, MSC-FFM, has entered clinical routine in Germany where it is licensed with a national hospital exemption authorization. We previously reported satisfying initial clinical outcomes, which we are now updating. The data were collected in our post-approval pharmacovigilance program, i.e., this is not a clinical study and the data is high-level and non-monitored.
(3) Results: Follow-up for 92 recipients of MSC-FFM was reported, 88 with GvHD ≥°III, one-third only steroid-refractory and two-thirds therapy resistant (refractory to steroids plus ≥2 additional lines of treatment). A median of three doses of MSC-FFM was administered without apparent toxicity. Overall response rates were 82% and 81% at the first and last evaluation, respectively. At six months, the estimated overall survival was 64%, while the cumulative incidence of death from underlying disease was 3%.
(4) Conclusions: MSC-FFM promises to be a safe and efficient treatment for severe R-aGvHD.
Introduction: Recent animal studies have shown that the alternate renin-angiotensin system (RAS) consisting of angiotensin-converting enzyme 2 (ACE2), angiotensin-(1–7) (Ang-(1–7)) and the Mas receptor is upregulated in cirrhosis and contributes to splanchnic vasodilatation and portal hypertension. To determine the potential relevance of these findings to human liver disease, we evaluated its expression and relationship to the patients’ clinical status in subjects with cirrhosis. Methods: Blood sampling from peripheral and central vascular beds was performed intra-operatively for cirrhotic patients at the time of liver transplantation (LT) or trans-jugular intra-hepatic portosystemic shunt (TIPS) procedures to measure angiotensin II (Ang II) and Ang-(1–7) peptide levels and ACE and ACE2 enzyme activity. Relevant clinical and hemodynamic data were recorded pre-operatively for all subjects and peripheral blood sampling was repeated 3 months or later post-operatively. Results: Ang-(1–-7) and ACE2 activity were up-regulated more than twofold in cirrhotic subjects both at the time of LT and TIPS and levels returned to comparable levels as control subjects post-transplantation. Ang-(1–7) levels correlated positively with the degree of liver disease severity, as measured by the model for an end-stage liver disease (MELD) and also with clinical parameters of pathological vasodilatation including cardiac output (CO). There were strong correlations found between the ACE2:ACE and the Ang-(1–7):Ang II ratio highlighting the inter-dependence of the alternate and classical arms of the RAS and thus their potential impact on vascular tone. Conclusions: In human cirrhosis, the alternate RAS is markedly upregulated and the activation of this system is associated strongly with features of the hyperdynamic circulation in advanced human cirrhosis.
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group’s cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The “ex-novo” occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies’ positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.
Endometriosis represents nowadays a real burden for the patients as well as for the physicians, as it requires surgical and/or medical treatment, often long – termed and repeated. Moreover, the high costs necessary to diagnose and treat endometriosis represent a real economic burden, being comparable to other chronic diseases like diabetes or rheumatoid arthritis. Therefore, the physicians dealing with this disease should take into account not only the efficacy of the treatment, but also the economic aspects and patients compliance.
The present paper analyses the efficiency of progestins (lynestrenol and medrogestone) in endometriosis as a cost – effective, but forgotten medical therapy of the disease. Our study underlines the good tolerability of progestins, as they have limited side effects, the compliance of patients being high. They are also low-cost medications, which could represent an effective alternative method in the endometriosis treatment, especially in less – developed countries that cannot afford the higher therapeutic costs.
Brain metastases are the most common intracranial tumor in adults and are associated with poor patient prognosis and median survival of only a few months. Treatment options for brain metastasis patients remain limited and largely depend on surgical resection, radio- and/or chemotherapy. The development and pre-clinical testing of novel therapeutic strategies require reliable experimental models and diagnostic tools that closely mimic technologies that are used in the clinic and reflect histopathological and biochemical changes that distinguish tumor progression from therapeutic response. In this study, we sought to test the applicability of magnetic resonance (MR) spectroscopy in combination with MR imaging to closely monitor therapeutic efficacy in a breast-to-brain metastasis model. Given the importance of radiotherapy as the standard of care for the majority of brain metastases patients, we chose to monitor the post-irradiation response by magnetic resonance spectroscopy (MRS) in combination with MR imaging (MRI) using a 7 Tesla small animal scanner. Radiation was applied as whole brain radiotherapy (WBRT) using the image-guided Small Animal Radiation Research Platform (SARRP). Here we describe alterations in different metabolites, including creatine and N-acetylaspartate, that are characteristic for brain metastases progression and lactate, which indicates hypoxia, while choline levels remained stable. Radiotherapy resulted in normalization of metabolite levels indicating tumor stasis or regression in response to treatment. Our data indicate that the use of MR spectroscopy in addition to MRI represents a valuable tool to closely monitor not only volumetrical but also metabolic changes during tumor progression and to evaluate therapeutic efficacy of intervention strategies. Adapting the analytical technology in brain metastasis models to those used in clinical settings will increase the translational significance of experimental evaluation and thus contribute to the advancement of pre-clinical assessment of novel therapeutic strategies to improve treatment options for brain metastases patients.
A novel osteotomy preparation technique to preserve implant site viability and enhance osteogenesis
(2019)
The preservation of bone viability at an osteotomy site is a critical variable for subsequent implant osseointegration. Recent biomechanical studies evaluating the consequences of site preparation led us to rethink the design of bone-cutting drills, especially those intended for implant site preparation. We present here a novel drill design that is designed to efficiently cut bone at a very low rotational velocity, obviating the need for irrigation as a coolant. The low-speed cutting produces little heat and, consequently, osteocyte viability is maintained. The lack of irrigation, coupled with the unique design of the cutting flutes, channels into the osteotomy autologous bone chips and osseous coagulum that have inherent osteogenic potential. Collectively, these features result in robust, new bone formation at rates significantly faster than those observed with conventional drilling protocols. These preclinical data have practical implications for the clinical preparation of osteotomies and alveolar bone reconstructive surgeries.
Background: Patients with chronic kidney disease (CKD) have considerable cardiovascular morbidity and mortality. Aortic stiffness is an independent predictor of cardiovascular risk and related to left ventricular remodeling and heart failure. Myocardial fibrosis is the pathophysiological hallmark of the failing heart.
Methods and results: An observational study of consecutive CKD patients (n = 276) undergoing comprehensive clinical cardiovascular magnetic resonance imaging. The relationship between aortic stiffness, myocardial fibrosis, left ventricular remodeling and the severity of chronic kidney disease was examined. Compared to age-gender matched controls with no known kidney disease (n = 242), CKD patients had considerably higher myocardial native T1 and central aortic PWV (p ≪ 0.001), as well as abnormal diastolic relaxation by E/e′ (mean) by echocardiography (p ≪ 0.01). A third of all patients had LGE, with similar proportions for the presence and the (ischaemic and non-ischaemic) pattern between the groups. PWV was strongly associated with and age, NT-proBNP and native T1 in both groups, but not with LGE presence or type; the associations were amplified in severe CKD stages. In multivariate analyses, PWV was independently associated with native T1 in both groups (p ≪ 0.01) with near two-fold increase in adjusted R2 in the presence of CKD (native T1 (10 ms) R2, B(95%CI) CKD vs. non-CKD 0.28, 0.2(0.15–0.25) vs. 0.18, 0.1(0.06–0.15), p ≪ 0.01).
Conclusions: Aortic stiffness and interstitial myocardial fibrosis are interrelated; this association is accelerated in the presence of CKD, but independent of LGE. Our findings reiterate the significant contribution of CKD-related factors to the pathophysiology of cardiovascular remodeling.
Myogenic vasoconstriction is an autoregulatory function of small arteries. Recently, G-protein-coupled receptors have been involved in myogenic vasoconstriction, but the downstream signalling mechanisms and the in-vivo-function of this myogenic autoregulation are poorly understood. Here, we show that small arteries from mice with smooth muscle-specific loss of G12/G13 or the Rho guanine nucleotide exchange factor ARHGEF12 have lost myogenic vasoconstriction. This defect was accompanied by loss of RhoA activation, while vessels showed normal increases in intracellular [Ca2+]. In the absence of myogenic vasoconstriction, perfusion of peripheral organs was increased, systemic vascular resistance was reduced and cardiac output and left ventricular mass were increased. In addition, animals with defective myogenic vasoconstriction showed aggravated hypotension in response to endotoxin. We conclude that G12/G13- and Rho-mediated signaling plays a key role in myogenic vasoconstriction and that myogenic tone is required to maintain local and systemic vascular resistance under physiological and pathological condition.
Background: With the current study, we aimed to determine the prevalence of back pain in employees of a German chemical company. We put a specific focus on disabling back pain and its association with sociodemographic, lifestyle- and work-related characteristics.
Methods: We used cross-sectional data, surveyed in health check-ups between 2011 and 2014 in Ludwigshafen am Rhein (Germany). A blood sample, physical examination and anamnesis by an occupational health physician as well as a written questionnaire were part of the check-up. A modified version of the Standardised Nordic Musculoskeletal Questionnaire was utilized to survey the back-pain specific information. Disabling back pain was defined as presence of any back pain in the past 12 months which prevented employees from carrying out their usual working tasks. We used multinomial logistic regression analysis to assess the association between (categorical) duration of disabling back pain and sociodemographic, lifestyle-, and work-related characteristics.
Results: Overall, 17,351 employees participated in the health check-up, information on 16,792 persons could be used for analyses. Participants were on average 43.7 (SD: 9.7) years old and mainly male (79.1%). Lifetime-, 12-months-, and 7-days-prevalence of any type and duration of back pain were 72.5, 66.1, and 27.1% respectively. About one third (33.5%) had suffered from an episode of disabling back pain, 16.7% 1–7 days, 10.3% 8–30 days, and 6.5% more than 30 days. Multinomial regression analysis yielded that 8–30 days or more than 30 days of disabling back pain (relative to 0 days) were more likely with older age, female gender, being married, former or current smoking, lower occupational status, higher work-related stress score, history of a spinal injury, and diagnosed dorsopathy.
Conclusions: There is a great need for action regarding multifaceted preventive measures and early interventions, especially for manual workers, older employees and women, where occupational medicine can play a decisive role.
Electrical stimulation shifts healing/scarring towards regeneration in a rat limb amputation model
(2019)
Different species respond differently to severe injury, such as limb loss. In species that regenerate, limb loss is met with complete restoration of the limbs’ form and function, whereas in mammals the amputated limb’s stump heals and scars. In in vitro studies, electrical stimulation (EStim) has been shown to promote cell migration, and osteo- and chondrogenesis. In in vivo studies, after limb amputation, EStim causes significant new bone, cartilage and vessel growth. Here, in a rat model, the stumps of amputated rat limbs were exposed to EStim, and we measured extracellular matrix (ECM) deposition, macrophage distribution, cell proliferation and gene expression changes at early (3 and 7 days) and later stages (28 days). We found that EStim caused differences in ECM deposition, with less condensed collagen fibrils, and modified macrophage response by changing M1 to M2 macrophage ratio. The number of proliferating cells was increased in EStim treated stumps 7 days after amputation, and transcriptome data strongly supported our histological findings, with activated gene pathways known to play key roles in embryonic development and regeneration. In conclusion, our findings support the hypothesis that EStim shifts injury response from healing/scarring towards regeneration. A better understanding of if and how EStim controls these changes, could lead to strategies that replace scarring with regeneration.
Cross-frequency coupling of sleep oscillations is thought to mediate memory consolidation. While the hippocampus is deemed central to this process, detailed knowledge of which oscillatory rhythms interact in the sleeping human hippocampus is lacking. Combining intracranial hippocampal and non-invasive electroencephalography from twelve neurosurgical patients, we characterized spectral power and coupling during non-rapid eye movement (NREM) and rapid eye movement (REM) sleep. Hippocampal coupling was extensive, with the majority of channels expressing spectral interactions. NREM consistently showed delta–ripple coupling, but ripples were also modulated by slow oscillations (SOs) and sleep spindles. SO–delta and SO–theta coupling, as well as interactions between delta/theta and spindle/beta frequencies also occurred. During REM, limited interactions between delta/theta and beta frequencies emerged. Moreover, oscillatory organization differed substantially between i) hippocampus and scalp, ii) sites along the anterior-posterior hippocampal axis, and iii) individuals. Overall, these results extend and refine our understanding of hippocampal sleep oscillations.
Background: For the prevention of attacks of hereditary angioedema (HAE), the efficacy and safety of subcutaneous human C1-esterase inhibitor (C1-INH[SC]; HAEGARDA®, CSL Behring) was established in the 16-week COMPACT trial.
Objective: To assess the long-term safety, occurrence of angioedema attacks, and use of rescue medication with C1-INH(SC).
Methods: Open-label, randomised, parallel-arm extension of COMPACT across 11 countries. Patients with frequent angioedema attacks, either study treatment-naïve or who had completed the COMPACT trial, were randomly assigned (1:1) to 40 IU/kg or 60 IU/kg C1-INH(SC) twice per week, with conditional up-titration to optimise prophylaxis. ClinicalTrials.gov registration: NCT02316353.
Results: 126 patients with a monthly attack rate of 4.3 in 3 months prior to entry in the COMPACT program were enrolled and treated for a mean of 1·5 years; 44 patients (34·9%) had >2 years exposure. Median steady-state C1-INH functional activity increased to a maximum of 73.0% with 60 IU/kg. Incidence of adverse events was low and similar in both dose groups (11·3 and 8·5 events per patient-year for 40 IU/kg and 60 IU/kg, respectively). For 40 IU/kg and 60 IU/kg, median annualised attack rates were 1·3 and 1·0, respectively and median rescue medication use was 0.2 and 0.0 times per year, respectively. Of 23 patients receiving 60 IU/kg for >2 years, 19 (83%) were attack-free during months 25–30 of treatment.
Conclusion: In patients with frequent HAE attacks, long-term replacement therapy with C1-INH(SC) is safe and exhibits a substantial and sustained prophylactic effect, with the vast majority of patients becoming free from debilitating disease symptoms.
Background: Two large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer Intervention Study II [IBIS-II]). Here, we report blinded long-term follow-up results for the IBIS-II trial, which compared anastrozole with placebo, with the objective of determining the efficacy of anastrozole for preventing breast cancer (both invasive and ductal carcinoma in situ) in the post-treatment period.
Methods: IBIS-II is an international, randomised, double-blind, placebo-controlled trial. Postmenopausal women at increased risk of developing breast cancer were recruited and were randomly assigned (1:1) to either anastrozole (1 mg per day, oral) or matching placebo daily for 5 years. After treatment completion, women were followed on a yearly basis to collect data on breast cancer incidence, death, other cancers, and major adverse events (cardiovascular events and fractures). The primary outcome was all breast cancer.
Findings: 3864 women were recruited between Feb 2, 2003, and Jan 31, 2012. 1920 women were randomly assigned to 5 years anastrozole and 1944 to placebo. After a median follow-up of 131 months (IQR 105–156), a 49% reduction in breast cancer was observed for anastrozole (85 vs 165 cases, hazard ratio [HR] 0·51, 95% CI 0·39–0·66, p<0·0001). The reduction was larger in the first 5 years (35 vs 89, 0·39, 0·27–0·58, p<0·0001), but still significant after 5 years (50 vs 76 new cases, 0·64, 0·45–0·91, p=0·014), and not significantly different from the first 5 years (p=0·087). Invasive oestrogen receptor-positive breast cancer was reduced by 54% (HR 0·46, 95% CI 0·33–0·65, p<0·0001), with a continued significant effect in the period after treatment. A 59% reduction in ductal carcinoma in situ was observed (0·41, 0·22–0·79, p=0·0081), especially in participants known to be oestrogen receptor-positive (0·22, 0·78–0·65, p<0·0001). No significant difference in deaths was observed overall (69 vs 70, HR 0·96, 95% CI 0·69–1·34, p=0·82) or for breast cancer (two anastrozole vs three placebo). A significant decrease in non-breast cancers was observed for anastrozole (147 vs 200, odds ratio 0·72, 95% CI 0·57–0·91, p=0·0042), owing primarily to non-melanoma skin cancer. No excess of fractures or cardiovascular disease was observed.
Interpretation: This analysis has identified a significant continuing reduction in breast cancer with anastrozole in the post-treatment follow-up period, with no evidence of new late side-effects. Further follow-up is needed to assess the effect on breast cancer mortality.
Funding: Cancer Research UK, the National Health and Medical Research Council Australia, Breast Cancer Research Foundation, Sanofi Aventis, and AstraZeneca.